TY - JOUR
T1 - Mechanistic and Etiological Similarities in Diabetes Mellitus and Alzheimer's Disease
T2 - Antidiabetic Drugs as Optimistic Therapeutics in Alzheimer's Disease
AU - Das, Subham
AU - Ramachandran, Anu Kunnath
AU - Halder, Debojyoti
AU - Akbar, Saleem
AU - Ahmed, Bahar
AU - Joseph, Alex
N1 - Funding Information:
Author Subham Das is thankful to Manipal Academy of Higher Education (MAHE) for Dr. T.M.A Pai Doctoral Fellowship. Author Anu Kunnath Ramachandran is thankful to the All India Council for Technical Education (AICTE) for National Doctoral Fellowship (NDF). Another author Saleem Akbar acknowledges the Indian Council of Medical Research (ICMR) for the Senior Research Fellowship (SRF). The authors also acknowledge the Manipal College of Pharmaceutical Sciences and Jamia Hamdard for providing facilities for this work. The authors also thank BioRen-der.com.
Publisher Copyright:
© 2023 Bentham Science Publishers.
PY - 2023
Y1 - 2023
N2 - BACKGROUND: Diabetes mellitus and Alzheimer's disease are two common diseases that majorly affect the elderly population. Patients in both cases are increasing day by day. They are considered two independent diseases, but recent evidence suggests that they have a lot in common. OBJECTIVE: In this review, we focused on the connection between Alzheimer's disease and diabetes and highlighted the importance of antidiabetic drugs against Alzheimer's disease. METHODS: Common pathways such as obesity, vascular diseases, oxidative stress, mitochondrial dysfunction, mutation of the ApoE4 gene, and Sirtuin gene were found to manipulate both diseases. Antidiabetic drugs are found to have promising effects on Alzheimer's disease, acting by reducing insulin resistance, neuronal protection, and reducing amyloid-beta plaques. Some anti-diabetic drugs have shown promising results in vivo and in vitro studies. RESULTS: No review present focuses on the structural features of the antidiabetic molecules against Alzheimer's disease, their crosslinking pathophysiology, the role of natural bioactive molecules, in silico advancements followed by preclinical and clinical studies, and current advancements. Hence, we concentrated on the factors mentioned in the objectives. CONCLUSION: Alzheimer's disease can be considered a form of 'type-3 diabetes,' and repurposing the anti-diabetic drug will open up new paths of research in the field of Alzheimer's disease drug discovery.
AB - BACKGROUND: Diabetes mellitus and Alzheimer's disease are two common diseases that majorly affect the elderly population. Patients in both cases are increasing day by day. They are considered two independent diseases, but recent evidence suggests that they have a lot in common. OBJECTIVE: In this review, we focused on the connection between Alzheimer's disease and diabetes and highlighted the importance of antidiabetic drugs against Alzheimer's disease. METHODS: Common pathways such as obesity, vascular diseases, oxidative stress, mitochondrial dysfunction, mutation of the ApoE4 gene, and Sirtuin gene were found to manipulate both diseases. Antidiabetic drugs are found to have promising effects on Alzheimer's disease, acting by reducing insulin resistance, neuronal protection, and reducing amyloid-beta plaques. Some anti-diabetic drugs have shown promising results in vivo and in vitro studies. RESULTS: No review present focuses on the structural features of the antidiabetic molecules against Alzheimer's disease, their crosslinking pathophysiology, the role of natural bioactive molecules, in silico advancements followed by preclinical and clinical studies, and current advancements. Hence, we concentrated on the factors mentioned in the objectives. CONCLUSION: Alzheimer's disease can be considered a form of 'type-3 diabetes,' and repurposing the anti-diabetic drug will open up new paths of research in the field of Alzheimer's disease drug discovery.
UR - http://www.scopus.com/inward/record.url?scp=85145482327&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145482327&partnerID=8YFLogxK
U2 - 10.2174/1871527321666220629162229
DO - 10.2174/1871527321666220629162229
M3 - Short survey
C2 - 35770411
AN - SCOPUS:85145482327
SN - 1871-5273
VL - 22
SP - 973
EP - 993
JO - CNS & neurological disorders drug targets
JF - CNS & neurological disorders drug targets
IS - 7
ER -